484 related articles for article (PubMed ID: 19204653)
1. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
Feusner JD; Kerwin L; Saxena S; Bystritsky A
Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
[TBL] [Abstract][Full Text] [Related]
2. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
Coric V; Taskiran S; Pittenger C; Wasylink S; Mathalon DH; Valentine G; Saksa J; Wu YT; Gueorguieva R; Sanacora G; Malison RT; Krystal JH
Biol Psychiatry; 2005 Sep; 58(5):424-8. PubMed ID: 15993857
[TBL] [Abstract][Full Text] [Related]
3. Open-label pilot study of memantine in the treatment of compulsive buying.
Grant JE; Odlaug BL; Mooney M; O'Brien R; Kim SW
Ann Clin Psychiatry; 2012 May; 24(2):119-26. PubMed ID: 22563566
[TBL] [Abstract][Full Text] [Related]
4. Error-related negativity abnormalities in generalized anxiety disorder and obsessive-compulsive disorder.
Xiao Z; Wang J; Zhang M; Li H; Tang Y; Wang Y; Fan Q; Fromson JA
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):265-72. PubMed ID: 21111024
[TBL] [Abstract][Full Text] [Related]
5. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
[TBL] [Abstract][Full Text] [Related]
6. A pilot double-blind treatment trial of memantine for alcohol dependence.
Evans SM; Levin FR; Brooks DJ; Garawi F
Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
[TBL] [Abstract][Full Text] [Related]
7. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
[TBL] [Abstract][Full Text] [Related]
8. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
Aboujaoude E; Barry JJ; Gamel N
J Clin Psychopharmacol; 2009 Feb; 29(1):51-5. PubMed ID: 19142108
[TBL] [Abstract][Full Text] [Related]
9. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
[TBL] [Abstract][Full Text] [Related]
10. Nicotine treatment of obsessive-compulsive disorder.
Lundberg S; Carlsson A; Norfeldt P; Carlsson ML
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Nov; 28(7):1195-9. PubMed ID: 15610934
[TBL] [Abstract][Full Text] [Related]
11. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment.
Saxena S; Maidment KM; Vapnik T; Golden G; Rishwain T; Rosen RM; Tarlow G; Bystritsky A
J Clin Psychiatry; 2002 Jan; 63(1):21-7. PubMed ID: 11838621
[TBL] [Abstract][Full Text] [Related]
12. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
Haghighi M; Jahangard L; Mohammad-Beigi H; Bajoghli H; Hafezian H; Rahimi A; Afshar H; Holsboer-Trachsler E; Brand S
Psychopharmacology (Berl); 2013 Aug; 228(4):633-40. PubMed ID: 23525525
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
Modarresi A; Chaibakhsh S; Koulaeinejad N; Koupaei SR
Psychiatry Res; 2019 Dec; 282():112602. PubMed ID: 31630042
[TBL] [Abstract][Full Text] [Related]
14. Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder.
Dougherty DD; Jameson M; Deckersbach T; Loh R; Thompson-Hollands J; Jenike M; Keuthen NJ
Int Clin Psychopharmacol; 2009 Nov; 24(6):306-11. PubMed ID: 19730388
[TBL] [Abstract][Full Text] [Related]
15. [Experimental study on sensory gating in generalized anxiety and obsessive compulsive disorders].
Xiao ZP; Chen XS; Wang JJ; Tang YX; Zhang TH; Zhang MD; Fan Q; Lou FY; Chen C
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(3):169-72. PubMed ID: 20356551
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial.
Farnia V; Gharehbaghi H; Alikhani M; Almasi A; Golshani S; Tatari F; Davarinejad O; Salemi S; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
J Psychiatr Res; 2018 Sep; 104():137-143. PubMed ID: 30044966
[TBL] [Abstract][Full Text] [Related]
17. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation.
Keck PE; Hsu HA; Papadakis K; Russo J
Clin Neuropharmacol; 2009; 32(4):199-204. PubMed ID: 19620854
[TBL] [Abstract][Full Text] [Related]
18. Memantine for comorbid obsessive-compulsive disorder and Asperger disorder suggests a link in glutamatergic dysregulation.
Bernhardt EB; Walsh KH; Posey DJ; McDougle CJ
J Clin Psychopharmacol; 2011 Oct; 31(5):673-5. PubMed ID: 21881459
[No Abstract] [Full Text] [Related]
19. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder.
Koran LM; Bromberg D; Hornfeldt CS; Shepski JC; Wang S; Hollander E
Compr Psychiatry; 2010; 51(4):373-9. PubMed ID: 20579510
[TBL] [Abstract][Full Text] [Related]
20. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Rabinowitz I; Baruch Y; Barak Y
Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
